HDAC9 and neoplasm: Further testing of the in vivo anti-tumor effect of combination of proteasome and HDAC inhibitors on more EBV-associated diseases, including a subset of Wp-restricted EBV-associated BL, post-transplant lymphoproliferative disorder, diffuse large B cell lymphoma and AIDS-associated lymphoproliferative disease is warranted.